The short version
4 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Cisatracurium Besylate
Cisatracurium Besylate · CISATRACURIUM BESYLATE 200 mg/20mL · Injection, Solution · Intravenous · Meitheal Pharmaceuticals Inc.
NDC 71288-0713-96 · 10 VIAL, SINGLE-DOSE in 1 CARTON / 20 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA211668
- TE code
- AP
- Approval date
- Apr 25, 2019
- Patents / exclusivity
- None on file
Shortage history
- Planned discontinuation — Cisatracurium Besylate, Injection, 20 mg/10 mL (2 mg/mL) Multidose Vial (NDC 0409-1208-01)May 6, 2026
- Planned discontinuation — Cisatracurium Besylate, Injection, 200 mg/20ml (10 mg/mL) Single Dose Vial (NDC 0409-1103-01)May 6, 2026
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Cisatracurium Besylate (Injection, Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Fresenius Kabi USA, LLC | CISATRACURIUM BESYLATE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Hospira, Inc. | CISATRACURIUM BESYLATE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Meitheal Pharmaceuticals Inc. | CISATRACURIUM BESYLATE 20 mg/10mL | Jul 15, 2026 | Sep 3, 2026 |
| Fresenius Kabi USA, LLC | CISATRACURIUM BESYLATE 10 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Hospira, Inc. | CISATRACURIUM BESYLATE 10 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Avenacy, LLC | CISATRACURIUM BESYLATE 10 mg/mL | Aug 18, 2026 | Sep 1, 2026 |
| Meitheal Pharmaceuticals Inc. | CISATRACURIUM BESYLATE 200 mg/20mL | Jul 15, 2026 | Aug 31, 2026 |
| Meitheal Pharmaceuticals Inc. | CISATRACURIUM BESYLATE 10 mg/5mL | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Cisatracurium Besylate — NDC 71288-0713-96," retrieved September 3, 2026, https://drugdashboards.com/drug/71288071396.
Free to cite with attribution — see how the data is put together.